CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report

Abstract

Aims: Circulating tumour cells (CTCs) can be detected in peripheral blood using their physical properties (increased size and less deformable than normal circulating blood cells) or using cell surface markers. The study of these CTCs should provide important insights into tumour biology, including mechanisms of drug resistance. We performed a pilot study (IRAS ID: 235459) to evaluate if CTCs could be isolated from peripheral blood samples collected from soft tissue sarcoma (STS) patients.

Methods: We used a combined approach that first enriched samples for CTCs using a microfluidic cassette via Parosrtix^TMPR1, and then sorted cells stained for vimentin and cytokeratin using the DEPArray^TM. The total circulating cell-free DNA (cfDNA) level was also analysed. Data were correlated with clinical parameters.

Results: 13 patients were recruited to this study: 7 patients with localised disease and 6 patients with metastatic disease. CTCs exhibited a high heterogeneity based on their expression of mesenchymal and epithelial markers. There was no significant difference in the number of CTCs between patients with localised versus metastatic disease. We observed no correlation between CTC numbers and cfDNA; however, the number of CTCs did correlate with primary tumour size.

Conclusion: The present study demonstrates the presence of CTCs in STS patients with localised and advanced disease. Further and larger studies are needed to characterise STS CTCs and to evaluate their prognostic significance.

Keywords

Circulating tumour cells / soft tissue sarcoma / metastasis

References

[1] Grünewald TG,Avnet S.Sarcoma treatment in the era of molecular medicine.EMBO Mol Med2020;12:e11131 PMCID:PMC7645378

[2] Hayes AJ,Strauss DC.UK guidelines for the management of soft tissue sarcomas.Br J Cancer2024;Online ahead of print:

[3] Tellez-Gabriel M,Young R,Heymann D.The challenges of detecting circulating tumor cells in sarcoma.Front Oncol2016;6:202 PMCID:PMC5013264

[4] Lin D,Luo M.Circulating tumor cells: biology and clinical significance.Signal Transduct Target Ther2021;6:404 PMCID:PMC8606574

[5] Brown HK,Cartron PF,Heymann MF.Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?.Drug Discov Today2019;24:763-72

[6] Satelli A,Cutrera JJ.Universal marker and detection tool for human sarcoma circulating tumor cells.Cancer Res2014;74:1645-50 PMCID:PMC3959622

[7] Hvichia GE,Wagner C.A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells.Int J Cancer2016;138:2894-904 PMCID:PMC5069649

[8] Le MN,Dopico PJ.Investigating surface proteins and antibody combinations for detecting circulating tumor cells of various sarcomas.Sci Rep2024;14:12374 PMCID:PMC11137101

[9] Mu H,Chen J.Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis.Cancer Biol Med2022;19:1397-409 PMCID:PMC9500224

[10] Vincenzi B,Zoccoli A.Circulating tumor cells in soft tissue sarcomas patients.Ann Oncol2012;23:ix489

[11] Blanchi J,Le Loarer F,Italiano A.Prognostic impact of circulating tumor cells in patients with soft-tissue sarcomas: a prospective study.Cancer Commun2023;43:391-4 PMCID:PMC10009659

[12] Vismara M,Silvestri M.Single-cell phenotypic and molecular characterization of circulating tumor cells isolated from cryopreserved peripheral blood mononuclear cells of patients with lung cancer and sarcoma.Clin Chem2022;68:691-701

[13] Hayashi M,McCarty G.Size-based detection of sarcoma circulating tumor cells and cell clusters.Oncotarget2017;8:78965-77 PMCID:PMC5668012

[14] Chinen LT,Abdallah EA.Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion.Onco Targets Ther2014;7:1609-17 PMCID:PMC4172081

[15] Schleiermacher G, Peter M, Oberlin O, et al; Société Française d'Oncologie Pédiatrique. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 2003;21:85-91.

[16] Yang J,Wang G.Mesenchymal to epithelial transition in sarcomas.Eur J Cancer2014;50:593-601

[17] Callegaro D,Bonvalot S.Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors.EClinicalMedicine2019;17:100215 PMCID:PMC6933187

[18] Jones RL,Brohl AS.Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial.JAMA Oncol2022;8:740-7 PMCID:PMC8972152

[19] Ravi V,Chawla SP.Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).JCO2018;36:e23570